Aurobindo Pharma and MSN Laboratories Pvt. Ltd. have opted to deal out of patent infringement litigation brought by AbbVie over the originator’s Fetzima (levomilnacipran hydrochloride) extended-release capsules, with a US district court agreeing to a pair of stipulations and proposed orders of dismissal.
Aurobindo And MSN Labs Join Others In Settling On Allergan’s Fetzima
Hikma Has Settlement Agreement And Only Approved ANDA
Two more ANDA companies have reached settlement agreements with AbbVie’s Allergan subsidiary and partner Pierre Fabre Medicament over proposed generic versions of the Fetzima serotonin and norepinephrine reuptake inhibitor.
More from Generics
• By
Generics Bulletin reviews global regulatory developments across the world.
• By
Aurobindo is set to join Lupin by competing against Johnson/Bayer’s blockbuster blood thinner Xarelto (rivaroxaban) 2.5mg tablets.
• By
As the Trump Administration continues to send ripples across industries, Tevogen has launched a new generic drugs-focused endeavor that plans to reshore production to the US.
• By
Sandoz has reached an agreement with AbbVie to dismiss without prejudice patent-infringement litigation involving more than 20 patents shielding the originator’s blockbuster JAK inhibitor Rinvoq.